Enoxaparin v warfarin for secondary prophylaxis of venous thromboembolism in patients with cancer and venous thromboembolism ‡
| Outcomes at 3 months | Enoxaparin | Warfarin | RRR (95% CI) | NNT (CI) |
|---|---|---|---|---|
| Treatment failure§ | 10% | 21% | 51% (−10 to 78) | Not significant |
| Major haemorrhage | 7% | 16% | 56% (−13 to 83) | Not significant |
| Fatal haemorrhage | 0% | 8% | 100% (35 to 100) | 13 (7 to 38) |
| Mortality | 11% | 23% | 50% (−4.9 to 77) | Not significant |
| RRI | NNH | |||
|---|---|---|---|---|
| ‡Abbreviations defined in glossary; RRR, RRI, NNT, NNH, and CI calculated from data in article. | ||||
| §Treatment failure = recurrent thromboembolism or major haemorrhage. | ||||
| Cancer progression | 17% | 13% | 27% (−40 to 170) | Not significant |